Literature DB >> 14634070

Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand.

Patrick Legembre1, Marie Beneteau, Sophie Daburon, Jean-François Moreau, Jean-Luc Taupin.   

Abstract

The 45 kDa Fas or CD95 receptor triggers apoptosis via the caspase cascade when stimulated by its ligand FasL or by agonistic Abs. Activated Fas receptors seem to oligomerize very early into SDS-stable and reducing agent-resistant microaggregates of 200-250 kDa on SDS-PAGE. However, these microaggregates have so far only been reported using agonistic anti-Fas Abs, and no results have been reported using FasL. Here, we demonstrate that the microaggregates do not form in response to FasL, while they always appear in response to the agonistic Ab, in four different cell lines and in normal lymphocytes from human blood. Therefore, the Fas microaggregates are not required for the induction of apoptosis via FasL. These results also suggest that subtle differences exist in the apoptotic pathways triggered by anti-Fas agonistic Abs and by FasL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634070     DOI: 10.4049/jimmunol.171.11.5659

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Hepatitis B Virus Surface Antigen Enhances the Sensitivity of Hepatocytes to Fas-Mediated Apoptosis via Suppression of AKT Phosphorylation.

Authors:  Zhen-Tang Jing; Wei Liu; Shu-Xiang Wu; Yun He; Yan-Ting Lin; Wan-Nan Chen; Xin-Jian Lin; Xu Lin
Journal:  J Immunol       Date:  2018-08-31       Impact factor: 5.422

2.  Palmitoylation of CD95 facilitates formation of SDS-stable receptor aggregates that initiate apoptosis signaling.

Authors:  Christine Feig; Vladimir Tchikov; Stefan Schütze; Marcus E Peter
Journal:  EMBO J       Date:  2006-12-07       Impact factor: 11.598

3.  Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.

Authors:  Sara Cuadrado-Castano; Juan Ayllon; Mena Mansour; Janis de la Iglesia-Vicente; Stefan Jordan; Shashank Tripathi; Adolfo García-Sastre; Enrique Villar
Journal:  Mol Cancer Ther       Date:  2015-03-11       Impact factor: 6.261

4.  Membrane-bound Fas ligand requires RIP1 for efficient activation of caspase-8 within the death-inducing signaling complex.

Authors:  Michael J Morgan; You-Sun Kim; Zheng-gang Liu
Journal:  J Immunol       Date:  2009-07-29       Impact factor: 5.422

5.  Establishment and Characterization of an In Vitro Model of Fas-Mediated Hepatocyte Cell Death.

Authors:  Mathieu Vinken; Michaël Maes; Sara Crespo Yanguas; Joost Willebrords; Tamara Vanhaecke; Vera Rogiers
Journal:  Methods Mol Biol       Date:  2015

6.  The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway.

Authors:  Sébastien Tauzin; Benjamin Chaigne-Delalande; Eric Selva; Nadine Khadra; Sophie Daburon; Cécile Contin-Bordes; Patrick Blanco; Jacques Le Seyec; Thomas Ducret; Laurent Counillon; Jean-François Moreau; Paul Hofman; Pierre Vacher; Patrick Legembre
Journal:  PLoS Biol       Date:  2011-06-21       Impact factor: 8.029

Review 7.  Experimental models of hepatotoxicity related to acute liver failure.

Authors:  Michaël Maes; Mathieu Vinken; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2015-11-26       Impact factor: 4.219

Review 8.  Primary hepatocytes and their cultures in liver apoptosis research.

Authors:  Mathieu Vinken; Michaël Maes; André G Oliveira; Bruno Cogliati; Pedro E Marques; Gustavo B Menezes; Maria Lúcia Zaidan Dagli; Tamara Vanhaecke; Vera Rogiers
Journal:  Arch Toxicol       Date:  2013-09-08       Impact factor: 5.153

9.  Precise mapping of the CD95 pre-ligand assembly domain.

Authors:  Valérie Edmond; Benoist Ghali; Aubin Penna; Jean-Luc Taupin; Sophie Daburon; Jean-François Moreau; Patrick Legembre
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Functional characterization of a chimeric soluble Fas ligand polymer with in vivo anti-tumor activity.

Authors:  Sophie Daburon; Christel Devaud; Pierre Costet; Aurore Morello; Laure Garrigue-Antar; Mike Maillasson; Nathalie Hargous; Delphine Lapaillerie; Marc Bonneu; Julie Dechanet-Merville; Patrick Legembre; Myriam Capone; Jean-François Moreau; Jean-Luc Taupin
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.